Gentian Diagnostics ASA OSL:GENT:
RENEWS LONG-TERM FAECAL CALPROTECTIN PARTNERSHIP WITH BÜHLMANN LABORATORIES
Gentian Diagnostics Renews Long-Term Partnership With Bühlmann Laboratories
Gentian Diagnostics ASA on 6ix
Earlier from Gentian Diagnostics
- Gentian Diagnostics ASA - Registration of share capital increase
- Calprotectin as a biomarker for immune dysfunction and 28‑day mortality in sepsis
- Gentian Diagnostics: Annual report 2025
- Mandatory notification of trade
- GENT: Record 2025 sales, strong US growth, new partnership, and NT-proBNP development setback
Later from Gentian Diagnostics
- Gentian Diagnostics: Invitation to presentation of first quarter results
- GENT: Q1 saw stable sales, NT-proBNP project termination, and a focus on new growth opportunities
- Serum calprotectin - marker of systemic inflammation and disease activity
- Gentian Diagnostics: Vatne Capital Reduces Indirect Ownership
- Join our R&D Team in Gothenburg
Follow Gentian Diagnostics into a list and get an email when it puts out news.
Follow Gentian Diagnostics